• Alexandre Docampo-Simón, María José Sánchez-Pujol, Adelina Gimeno-Gascon, Juan Carlos Palazón-Cabanes, Gloria Juan-Carpena, Eduardo Vergara-De Caso, Iris González-Villanueva, Mar Blanes-Martínez, and Isabel Betlloch-Mas.
• Department of Dermatology, Alicante University General Hospital, Alicante, Spain.
• Dermatol Ther. 2020 Nov 1; 33 (6): e14332.

AbstractChilblain-like acral lesions have been identified in some coronavirus disease 2019 (COVID-19) patients. It has been suggested that these pseudo-chilblains could be a specific marker of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with these lesions have had negative polymerase chain reactions (PCRs), but some authors believe serology tests are likely to give positive results. We designed a prospective study including all patients with pseudo-chilblains treated in outpatient department in April and May 2020 and then performed SARS-CoV-2 PCR and serology tests on all available patients. We evaluated 59 patients, of whom 17 had undergone PCR before the study period, all with negative results. For the present study, we performed 20 additional PCRs, serology tests in 25 patients, and a parvovirus B19 antibody test in 15 patients. All results were negative. Our findings counter the hypothesis that serology is likely to reveal SARS-CoV-2 infection in patients with pseudo-chilblains. One hypothesis for our negative results is that the time period between symptom onset and antibody production is longer in these patients; another is that the lesions are caused by behavioral changes during lockdown rather than SARS-CoV-2 infection. We nevertheless maintain that COVID-19 should be ruled out in people presenting with chilblain-like lesions.© 2020 Wiley Periodicals LLC.

29 keywords...

hide…